DSP Clinical Research Named to Inc. 5000 List of Fastest Growing U.S. Private Companies for 5th Time

FAIRFIELD, N.J., Sept. 21, 2018 /PRNewswire-PRWeb/ -- Contract Research Organization DSP Clinical Research announced it achieved a ranking of 3500 on the prestigious Inc. 5000 list. This is the fifth time DSP has earned a place on the list since 2003. DSP provides customized contract research services for small to mid-size biopharma and device companies conducting clinical trials in specialty populations such as women's health, reproductive endocrinology/infertility, endocrinology, and urology.

The Inc. 5000 is an exclusive ranking of the U.S.'s fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy - America's independent-minded entrepreneurs.

DSP founder and President Darlene Panzitta said, "We're grateful to earn recognition from Inc. for the fifth time. DSP continues our steady growth because we bring a proven, unique approach to every clinical study. We continue to focus on the unmet needs of small to mid-size biopharma and device companies. Our clients know when they come to DSP they'll get the highest quality data, personal and consistent attention, and no surprises."

About DSP Clinical Research

DSP Clinical Research is a specialty Contract Research Organization (CRO) dedicated to managing and executing Phase I-IV clinical studies. DSP drives top-tier success for small to mid-size biopharma and medical device companies through award-winning experience, passionate leadership and operational excellence. DSP is unique among CROs for using a monthly fixed-fee pricing model that identifies all clinical trial expenditures, adjustments, and costs ahead of the clinical trial. For more information visit http://www.dspclinical.com

SOURCE DSP Clinical Research